Drug intelligence / Profile preview

oncoxin (279bf0)

Development stage
Unknown
Lead developer
Catalysis
Modality
Small Molecules, Drug Delivery Systems
Administration
Oral
01

Overview

Oncoxin (also known as Ocoxin or Ocoxin Oral Solution) is an orally administered nutritional supplement composed of amino acids, vitamins, minerals, and a variety of natural antioxidants and plant extracts. It is designed to support cancer patients undergoing chemotherapy or radiotherapy by reducing treatment-related side effects such as oral mucositis and improving quality of life. Preclinical studies indicate that Oncoxin exerts antitumoral effects by slowing tumor cell proliferation and inducing apoptosis through mechanisms including cell cycle arrest at G2/M phase. The supplement also demonstrates antioxidant and anti-inflammatory properties. Clinical trials suggest it may help reduce the severity of adverse reactions to cancer therapies without significant toxicity[1][2][3][4][5].

Brand names
oncoxinocoxinocoxin oral solutiononcoxin-viusid
Other names
ocoxinocoxin oral solutiononcoxin-viusid
02

Targets

CHEK1 (Checkpoint kinase 1)CHEK2 (Checkpoint kinase 2)CCND1 (Cyclin D1)RB1 (Retinoblastoma-associated Protein)SLC30A1 (Solute carrier family 30 member 1)CDKN1B (Transmembrane emp24 domain-containing protein 7)

Beyond the preview

Go deeper on oncoxin (279bf0).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oncoxin (279bf0).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call